# ACE2 (Angiotensin-Converting Enzyme 2): Structural Biology, Viral Entry Receptor Function, and RAAS Regulation


## Key Takeaways

- ACE2 is a zinc-dependent metallocarboxypeptidase that acts as the primary host cell entry receptor for SARS-CoV and SARS-CoV-2, binding to the viral spike protein's receptor-binding domain (RBD).
- Located on the X chromosome, ACE2's expression is regulated by interferon stimulation, androgens, and epigenetic modifications, influencing sex-based differences in COVID-19 susceptibility and severity.
- The protein's peptidase domain (PD) is catalytically active, cleaving Angiotensin II (Ang II) to Angiotensin-(1-7) [Ang-(1-7)], thereby counter-regulating the pro-inflammatory and vasoconstrictive effects of the ACE-Ang II-AT1R axis.
- Viral binding to ACE2 triggers its downregulation and shedding via ADAM17, shifting the RAAS balance towards the pathological ACE/Ang II/AT1R axis and contributing to multi-organ injury in severe COVID-19.
- Therapeutic strategies targeting the ACE2-spike interaction include soluble ACE2 decoy receptors, monoclonal antibodies, and small-molecule inhibitors designed to block viral entry.
- Genetic polymorphisms in *ACE2* and variations in its expression due to epigenetic factors and comorbidities like smoking and obesity are critical determinants of host susceptibility and disease severity.

---

## Executive Summary & Key Metadata

Angiotensin-converting enzyme 2 (ACE2) is a type I transmembrane metallocarboxypeptidase that serves as the central counter-regulatory enzyme of the renin-angiotensin-aldosterone system (RAAS). Beyond its canonical enzymatic function—the cleavage of angiotensin II (Ang II) into angiotensin-(1–7) [Ang-(1–7)]—ACE2 is the principal host cell entry receptor for severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2, the etiological agent of coronavirus disease 2019 (COVID-19) [1, 2, 3]. The protein is encoded by the *ACE2* gene, which maps to the X chromosome, a feature with profound implications for sex-based differences in COVID-19 susceptibility and cardiovascular pathology [4, 5]. ACE2 is expressed across a wide variety of human tissues, including the lungs, heart, kidneys, testes, and gastrointestinal tract, making it a determinant of multi-organ tropism for SARS-CoV-2 [1, 6, 7, 8]. This reference manual provides an exhaustive analysis of the *ACE2* gene, from its genomic architecture and 3D structural biology to its signaling pathways, pathogenic mutations, viral interactions, and pharmacogenomic relevance.

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | ACE2 |
| **UniProt Accession** | Q9BYF1 |
| **Representative PDB ID** | 6M0J |
| **Chromosomal Locus** | Xp22.2 |
| **Primary Molecular Function** | Zinc-dependent metallocarboxypeptidase; cleaves Ang II to Ang-(1–7); host receptor for SARS-CoV and SARS-CoV-2 |
| **Disease & Pathology Associations** | COVID-19 susceptibility/severity, hypertension, cardiovascular disease, heart failure, pulmonary arterial hypertension, Alzheimer's disease, acute lung injury/ARDS, preeclampsia [9, 10, 11, 12, 13, 14, 15, 16] |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *ACE2* gene is located on the short arm of the X chromosome at cytogenetic band Xp22.2. This chromosomal assignment is of considerable clinical significance; because males are hemizygous for X-linked genes, they possess only a single copy of *ACE2*, whereas females carry two alleles subject to X-inactivation. This genetic architecture has been hypothesized to contribute to the observed sex-specific differences in COVID-19 severity and mortality, with males exhibiting higher hospitalization and fatality rates [1, 4, 5]. The gene spans approximately 40 kilobases (kb) of genomic DNA and comprises 18 exons, which encode a mature protein of 805 amino acids [2, 3]. The genomic structure is highly conserved across mammals, reflecting its essential physiological roles in cardiovascular and renal homeostasis [16].

### 1.2 Promoter Architecture and Transcriptional Regulation

The 5' flanking region of *ACE2* contains a canonical TATA-less promoter enriched in GC content, a feature common to housekeeping and broadly expressed genes. Multiple transcription factor binding sites have been identified *in silico* and validated experimentally, including binding motifs for Specificity Protein 1 (Sp1), which is critical for basal transcriptional activity. The promoter also harbors response elements for members of the signal transducer and activator of transcription (STAT) family, particularly STAT1 and STAT3, which mediate the transcriptional response to interferons (IFNs). This is a key regulatory node: *ACE2* has been characterized as an interferon-stimulated gene (ISG) in human airway epithelial cells. Upon stimulation with type I or type II interferons (IFN-α, IFN-β, and IFN-γ), there is a significant upregulation of *ACE2* mRNA and protein, a mechanism that may paradoxically enhance viral entry during the innate immune response to SARS-CoV-2 infection [1, 4].

Epigenetic regulation also plays a substantial role in *ACE2* expression. DNA methylation analysis of the *ACE2* promoter region in respiratory tissues has revealed age- and sex-dependent methylation patterns. Specifically, differential methylation at CpG sites within the promoter and first exon correlates with transcriptional activity, providing a mechanistic link between advancing age, epigenetic drift, and increased susceptibility to severe COVID-19 [5]. Furthermore, the promoter region is responsive to androgenic signaling, as androgen response elements (AREs) have been identified. This finding connects androgen levels to ACE2 expression and provides a rationale for the observed association between androgen exposure and COVID-19 severity [6, 7].

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveal that the *ACE2* locus is embedded within a topologically associating domain (TAD) that includes several putative enhancer elements. These enhancers are marked by histone H3 lysine 27 acetylation (H3K27ac) and are bound by transcription factors such as FOXA1 and GATA4 in tissue-specific manners. The interaction between the *ACE2* promoter and these distal enhancers is cell-type specific, explaining the high expression in type II alveolar epithelial cells (AT2), enterocytes, and proximal tubular cells of the kidney, while expression remains low in most peripheral blood immune cells [1, 6, 8].

### 1.4 Alternative Splicing and Isoforms

While the canonical transcript (ENST00000252519) encodes the full-length 805-amino acid protein, several alternative splicing isoforms have been cataloged in Ensembl and RefSeq. A notable isoform, ACE2-TV1, lacks a portion of the juxtamembrane stalk region but retains the peptidase domain and transmembrane anchor. Another isoform, ACE2-TV2, is predicted to encode a soluble, secreted form of the protein lacking the transmembrane domain. The existence of a soluble ACE2 (sACE2) isoform is physiologically relevant; sACE2 is generated primarily via proteolytic cleavage of the membrane-bound form by the metalloprotease ADAM17 (a disintegrin and metalloproteinase 17), but alternatively spliced transcripts may contribute to the circulating pool [9, 10]. Circulating sACE2 retains enzymatic activity and can neutralize SARS-CoV-2 by acting as a decoy receptor, a property exploited in therapeutic development [10].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Boundaries

The ACE2 protein is a type I integral membrane glycoprotein composed of 805 amino acids with a predicted molecular weight of approximately 92 kDa (unmodified) and 120 kDa (glycosylated) [2, 3]. The protein is organized into distinct functional domains from the N-terminus to the C-terminus:

1.  **Signal Peptide (aa 1–17):** Directs the nascent polypeptide to the endoplasmic reticulum for co-translational translocation into the secretory pathway.
2.  **N-Terminal Peptidase Domain (PD) (aa 18–614):** This large extracellular domain is the catalytic ectodomain. It shares approximately 42% sequence identity with the N-terminal domain of human angiotensin-converting enzyme (ACE), but functions as a carboxypeptidase rather than a dipeptidyl carboxypeptidase [2, 11]. This domain contains the zinc-binding motif (HEXXH) and is responsible for both the enzymatic activity and the binding of the SARS-CoV-2 spike protein [12, 13].
3.  **Collectrin-like Domain (CLD) (aa 615–740):** This domain shares homology with collectrin, a protein involved in amino acid transport. The CLD is critical for the association of ACE2 with the amino acid transporter B⁰AT1 (SLC6A19), facilitating the intestinal absorption of neutral amino acids [14].
4.  **Transmembrane Helix (TM) (aa 741–768):** A single-pass hydrophobic alpha-helix that anchors ACE2 to the plasma membrane.
5.  **Cytoplasmic Tail (aa 769–805):** A short intracellular domain containing phosphorylation sites and a PDZ-binding motif (SLL) at the extreme C-terminus. This motif mediates interactions with PDZ-domain-containing scaffolding proteins, such as NHERF1, which regulate receptor localization and signaling [14].

### 2.2 Quaternary Structure and Cryo-EM Analysis

High-resolution cryo-electron microscopy (cryo-EM) structures of full-length human ACE2 in complex with the SARS-CoV-2 spike receptor-binding domain (RBD) have been resolved, most notably PDB entry 6M0J [13]. These structures reveal that ACE2 exists as a homodimer on the cell surface. The dimerization interface is formed primarily by the CLD domains, creating a "clam-shell" arrangement where the two PDs are positioned to bind the trimeric spike protein of the virus. The cryo-EM structure at 2.9 Å resolution (6M0J) demonstrated that the SARS-CoV-2 RBD binds to the extracellular PD of ACE2, with the interaction dominated by polar contacts at the N-terminal helix of the PD. Key residues involved in this interface include Lys31, Glu35, Asp38, Tyr41, Gln42, Lys353, and Arg357 on ACE2, which form hydrogen bonds and salt bridges with residues on the viral RBD [12, 13].

### 2.3 Catalytic Mechanism and Active Site

The catalytic activity of ACE2 resides in the PD, which contains a zinc ion coordinated by two histidines (His374 and His378) and a glutamate (Glu402) within the HEXXH consensus sequence, along with a water molecule. The catalytic mechanism involves the polarization of a water molecule by the zinc ion, enabling nucleophilic attack on the scissile peptide bond of the substrate. ACE2 is a strict carboxypeptidase, removing a single C-terminal residue from its substrates. Its primary physiological substrate is Ang II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe), from which it removes the C-terminal phenylalanine to generate Ang-(1–7) [11, 15]. It also cleaves other peptides, including apelin-13 and des-Arg⁹-bradykinin, but with lower efficiency. The active site is a deep, narrow channel that accommodates the C-terminus of the substrate, and its specificity is determined by the S2' subsite, which preferentially accommodates a proline residue [11].

### 2.4 Post-Translational Modifications

ACE2 is heavily glycosylated, with multiple N-linked glycosylation sites (e.g., Asn53, Asn90, Asn103, Asn322, Asn432, Asn546, and Asn690) that are critical for proper protein folding, stability, and cell-surface trafficking [16]. The glycans also play a role in modulating the interaction with the viral spike protein. Additionally, the cytoplasmic tail contains cysteine residues that can be palmitoylated, influencing membrane microdomain localization. The ectodomain is subject to regulated intramembrane proteolysis: ADAM17 cleaves ACE2 at a site near the transmembrane domain, resulting in the release of sACE2 into the extracellular space. This shedding process is enhanced by inflammatory stimuli and is a key mechanism for the downregulation of cell-surface ACE2 during SARS-CoV-2 infection [1, 16].

> **[Interactive 3D Protein Visualizer: Load ACE2 (PDB: 6M0J)](/tools/protein-structure-viewer?source=direct&pdbId=6M0J)**

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Renin-Angiotensin-Aldosterone System (RAAS) Axis

ACE2 is a master regulator of the RAAS, functioning as a negative regulator of the classical ACE-Ang II-AT1R axis. In the classical pathway, renin cleaves angiotensinogen to angiotensin I (Ang I), which is then converted to the potent vasoconstrictor Ang II by ACE. Ang II exerts its effects primarily through the angiotensin II type 1 receptor (AT1R), promoting vasoconstriction, sodium retention, inflammation, fibrosis, and oxidative stress. ACE2 counterbalances this system by cleaving Ang II to generate Ang-(1–7), which acts on the Mas receptor (MasR) to elicit vasodilatory, anti-inflammatory, anti-fibrotic, and anti-proliferative effects [2, 3, 14]. This ACE2/Ang-(1–7)/MasR axis is a critical protective pathway in the cardiovascular, renal, and pulmonary systems [4, 16].

### 3.2 Downstream Signaling Cascades

The binding of Ang-(1–7) to MasR activates a cascade of intracellular signaling pathways. These include the activation of phosphatidylinositol 3-kinase (PI3K) and protein kinase B (Akt), leading to endothelial nitric oxide synthase (eNOS) phosphorylation and increased nitric oxide (NO) production. This pathway promotes vasodilation and endothelial cell survival. Additionally, MasR activation inhibits mitogen-activated protein kinase (MAPK) signaling pathways, such as ERK1/2 and p38, reducing cellular proliferation and fibrosis [3, 4]. In the context of acute lung injury, the ACE2/Ang-(1–7)/MasR axis has been shown to attenuate pulmonary vascular permeability and inflammation, protecting against the development of acute respiratory distress syndrome (ARDS) [9, 11].

### 3.3 Protein-Protein Interaction Networks

Beyond its enzymatic function, ACE2 is a scaffolding protein. Its C-terminal PDZ-binding motif interacts with the sodium/hydrogen exchanger regulatory factor 1 (NHERF1), which links ACE2 to the actin cytoskeleton and influences its apical membrane localization in polarized epithelial cells. This interaction is essential for the role of ACE2 in the intestinal amino acid transporter complex with B⁰AT1 [14]. During SARS-CoV-2 infection, the interaction between the viral spike protein and ACE2 triggers the downregulation of cell-surface ACE2. This downregulation is mediated by the activation of ADAM17 and the subsequent shedding of the ectodomain. The loss of ACE2 from the cell surface shifts the RAAS balance towards the pathological ACE/Ang II/AT1R axis, contributing to the multi-organ injury observed in severe COVID-19 [1, 5, 11]. The interaction network also includes TMPRSS2 (transmembrane serine protease 2), which primes the spike protein for membrane fusion, and is co-expressed with ACE2 in several tissues [6].

### 3.4 Regulation by MicroRNAs and Exosomes

ACE2 expression is also regulated at the post-transcriptional level by microRNAs (miRNAs). For instance, miR-1246 has been shown to directly target the 3' untranslated region (UTR) of *ACE2* mRNA, leading to its degradation and a subsequent decrease in ACE2 protein levels. This regulation is relevant in the context of lipopolysaccharide (LPS)-induced acute lung injury, where miR-1246-mediated downregulation of ACE2 exacerbates pulmonary endothelial cell apoptosis [7]. Furthermore, ACE2 can be transferred between cells via exosomes. Exosomes derived from endothelial progenitor cells (EPCs) have been shown to carry ACE2 mRNA and protein, which can be taken up by recipient endothelial cells, enhancing their survival and function under stress conditions [8].

### 3.5 Signaling Pathway Diagram

```mermaid
flowchart TD
    A["Angiotensinogen"] -->|"Renin"| B["Angiotensin I"]
    B -->|"ACE"| C["Angiotensin II"]
    C -->|"Binds"| D["AT1R"]
    D --> E["Vasoconstriction, Inflammation, Fibrosis"]
    
    C -->|"ACE2 Cleavage"| F["Ang-(1-7)"]
    F -->|"Binds"| G["MasR"]
    G --> H["Vasodilation, Anti-inflammation, Anti-fibrosis"]
    
    I["SARS-CoV-2 Spike"] -->|"Binds"| J["ACE2 Receptor"]
    J -->|"Downregulation & Shedding"| K["ADAM17"]
    K --> L["Soluble ACE2"]
    J -->|"Loss of Function"| M["↑ Ang II / ↓ Ang-(1-7)"]
    M --> N["Exacerbated Tissue Injury"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Genetic Polymorphisms and Disease Association

The *ACE2* gene is highly polymorphic, with numerous single nucleotide polymorphisms (SNPs) cataloged in dbSNP. Several of these variants have been investigated for their association with essential hypertension, cardiovascular disease, and COVID-19 severity [9, 10, 11, 12, 13, 14]. Initial studies in Australian and Chinese Han populations found no significant association between common *ACE2* SNPs and essential hypertension [10, 11]. However, subsequent studies have identified specific variants that may modulate disease risk. For example, the SNP rs2285666, located in an intronic region, has been associated with altered ACE2 expression levels and enzymatic activity, and has been linked to hypertension in some populations [12, 15]. A meta-analysis of *ACE2* variants and COVID-19 severity identified several polymorphisms, including rs2285666 and rs2074192, that may influence susceptibility to infection and disease progression, although results have been inconsistent across cohorts [9, 13, 16].

### 4.2 Structural Hotspot Mutations Affecting Viral Entry

Given the critical role of the ACE2-RBD interface in viral entry, non-synonymous mutations in the peptidase domain that alter the amino acid sequence at the binding interface are of particular interest. Structural and computational analyses have identified key residues that, when mutated, could either enhance or reduce the binding affinity for the SARS-CoV-2 spike protein [1, 12]. For instance, mutations at positions 31 (Lys31), 35 (Glu35), and 38 (Asp38) have been shown to affect the electrostatic interactions with the viral RBD. While these variants are rare in the general population, they provide insight into the molecular determinants of host susceptibility and the potential for zoonotic spillover [1, 2]. Furthermore, the ability of ACE2 orthologs from different animal species to support SARS-CoV-2 entry is largely determined by sequence variation at these critical contact residues, explaining the broad host range of the virus [2].

### 4.3 Loss-of-Function and Gain-of-Function Variants

While complete loss-of-function mutations in *ACE2* are rare and often lethal in animal models, partial loss-of-function variants have been described. These variants can lead to reduced catalytic activity, resulting in an imbalance in the RAAS with increased Ang II levels and decreased Ang-(1–7) levels. This imbalance is associated with an increased risk of cardiovascular and renal diseases [16]. Conversely, certain variants may lead to increased ACE2 expression or activity, which could theoretically provide greater cardiovascular protection but also increase the number of entry points for SARS-CoV-2 [14]. The clinical impact of these variants is complex and context-dependent, influenced by factors such as age, sex, and the presence of comorbidities like obesity and diabetes [3, 4, 5].

### 4.4 Epigenetic and Expression-Level Variations

In addition to genetic polymorphisms, variations in *ACE2* expression due to epigenetic modifications and transcriptional regulation are clinically significant. DNA methylation at the *ACE2* promoter varies with age and sex, correlating with differential expression in the respiratory tract [5]. This epigenetic variation may contribute to the increased susceptibility of older adults and males to severe COVID-19 [5, 6]. Furthermore, conditions such as type 2 inflammation (e.g., asthma) have been shown to reduce ACE2 protein expression in bronchial and nasal epithelial cells, potentially explaining the lower risk of severe COVID-19 in some asthmatic patients [7]. Conversely, smoking and obesity have been associated with increased ACE2 expression in the lungs and adipose tissue, respectively, providing a mechanistic basis for their role as risk factors for severe disease [3, 8, 9, 10].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 SARS-CoV and SARS-CoV-2 Entry Mechanism

ACE2 was first identified as a functional receptor for SARS-CoV in 2003 [3]. The trimeric spike (S) glycoprotein of the virus mediates host cell entry. The S protein is cleaved by host proteases into the S1 and S2 subunits. The S1 subunit contains the receptor-binding domain (RBD), which directly binds to the extracellular peptidase domain of ACE2. Following receptor binding, the S2 subunit undergoes a conformational change that facilitates fusion between the viral envelope and the host cell membrane. This fusion requires the prior cleavage of the S protein at the S1/S2 boundary and the S2' site by host proteases, most notably TMPRSS2 [2, 11, 12]. The co-expression of ACE2 and TMPRSS2 in specific cell types, such as AT2 cells in the lung and enterocytes in the gut, determines the cellular tropism of the virus [1, 6].

### 5.2 Downregulation of ACE2 and Pathogenesis

The interaction between the SARS-CoV-2 spike protein and ACE2 does not merely facilitate viral entry; it also leads to the downregulation of cell-surface ACE2. Upon binding, the ACE2-spike complex is internalized, and the ectodomain is shed by ADAM17. This results in a net loss of ACE2 from the cell surface [1, 16]. Since ACE2 is a critical negative regulator of the RAAS, its loss shifts the balance towards the pathological ACE/Ang II/AT1R axis. The resulting increase in Ang II and decrease in Ang-(1–7) promotes vasoconstriction, inflammation, and fibrosis, contributing to the acute lung injury, ARDS, and multi-organ failure seen in severe COVID-19 [5, 9, 11, 13]. This mechanism was first demonstrated in a landmark study using SARS-CoV, which showed that ACE2 knockout mice were protected from severe lung injury, while injection of the SARS-CoV spike protein alone was sufficient to exacerbate lung damage via ACE2 downregulation [9].

### 5.3 Viral Evasion and Enhancement of Infection

Some coronaviruses have been shown to upregulate ACE2 expression to enhance their own infection. For example, it has been suggested that the SARS-CoV-2 spike protein itself, or other viral components, may signal to increase ACE2 expression in neighboring cells, thereby facilitating viral spread [14, 15]. Additionally, the interferon-mediated upregulation of ACE2, while part of the host antiviral response, can paradoxically provide more receptors for the virus, potentially increasing viral load [4]. This complex interplay between the host immune response and viral exploitation of ACE2 is a key area of ongoing research.

### 5.4 Broad Host Range and Zoonotic Potential

The ability of SARS-CoV-2 to infect a wide range of mammalian species is determined by the conservation of critical amino acid residues in ACE2 that interact with the viral RBD. Studies have shown that ACE2 orthologs from various animals, including cats, dogs, ferrets, and several non-human primates, can support SARS-CoV-2 entry, while others, such as mice and rats, cannot due to key sequence differences [2]. This broad receptor usage has implications for the zoonotic reservoir of the virus and the potential for spillback into animal populations. Furthermore, the continuous evolution of the viral spike protein, particularly in the RBD, has led to the emergence of variants with increased binding affinity for human ACE2, enhancing transmissibility [12, 16]. The potential for other coronaviruses, such as the bat-infecting merbecovirus HKU5-CoV lineage 2, to adapt to use human ACE2 highlights the ongoing pandemic threat [16].

---

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 Targeting the ACE2-Spike Protein Interaction

The central role of ACE2 in SARS-CoV-2 entry has made it a prime target for antiviral drug development. Therapeutic strategies can be broadly categorized into those that block the interaction between the viral spike protein and ACE2, and those that modulate ACE2 expression or activity.

**Soluble ACE2 (sACE2) and Decoy Receptors:** Recombinant human soluble ACE2 (rhACE2, e.g., APN01) acts as a decoy receptor. It binds to the viral spike protein with high affinity, neutralizing the virus and preventing it from attaching to membrane-bound ACE2. Clinical trials have investigated rhACE2 for the treatment of ARDS and COVID-19 [10]. A trimeric form of human ACE2 has been engineered to have an even higher avidity for the spike protein, enhancing its neutralizing potency [1].

**Monoclonal Antibodies:** Monoclonal antibodies (mAbs) targeting the ACE2-binding domain of the spike protein have been developed and received emergency use authorization for the treatment of COVID-19. These antibodies, such as bamlanivimab and casirivimab/imdevimab, block the RBD-ACE2 interaction, preventing viral entry. Conversely, antibodies targeting ACE2 itself have also been explored, though they carry the risk of inducing autoimmunity [2, 12].

**Small-Molecule Inhibitors and Natural Products:** High-throughput screening and *in silico* docking studies have identified various small molecules that can bind to the ACE2 peptidase domain or the RBD-ACE2 interface, potentially blocking viral entry. Natural flavonoids, such as quercetin and its metabolites, have been shown to inhibit ACE2 activity *in vitro* [3]. Other natural compounds, including components of essential oils from geranium and lemon, have been reported to downregulate ACE2 expression in epithelial cells [4]. However, the clinical efficacy of these compounds remains to be established [5, 6].

**Stapled Peptides:** Hydrocarbon-stapled peptides derived from the alpha-helical region of the ACE2 peptidase domain that interacts with the spike protein have been designed. These peptides mimic the binding interface and can potently inhibit SARS-CoV-2 infection *in vitro* by occupying the RBD [7].

### 6.2 Modulating ACE2 Expression and Activity

**RAAS Inhibitors:** There has been considerable debate regarding the use of ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) during the COVID-19 pandemic. Initial hypotheses suggested that these drugs might upregulate ACE2 expression, potentially increasing susceptibility to infection. However, subsequent clinical and genetic studies have largely refuted this, showing no association between ACEI/ARB use and increased ACE2 expression in the kidney or with COVID-19 severity [8, 9, 10, 11]. Current guidelines recommend that patients continue their RAAS inhibitor therapy.

**Androgen Receptor Antagonists:** Given the presence of androgen response elements in the *ACE2* promoter, androgen deprivation therapy or 5-alpha reductase inhibitors (e.g., finasteride) have been proposed as potential therapeutic strategies to reduce ACE2 expression and limit viral entry [6, 7]. Spironolactone, a mineralocorticoid receptor antagonist with anti-androgenic properties, has also been suggested as a potential protective agent [7]. However, clinical evidence for these approaches is limited.

**ACE2 Activators:** In the context of chronic diseases like hypertension and heart failure, enhancing ACE2 activity is a therapeutic goal. Peptides derived from food proteins, such as pea protein hydrolysate, have been identified as ACE2 up-regulators, offering a potential nutraceutical approach to boost the protective ACE2/Ang-(1–7)/MasR axis [12]. Gene therapy approaches using mesenchymal stem cells modified to overexpress ACE2 have shown promise in animal models of lung fibrosis [13].

### 6.3 [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles) of ACE2

The pharmacogenomics of *ACE2* is an emerging field. Genetic polymorphisms in *ACE2* have been studied for their impact on the antihypertensive efficacy of ACE inhibitors. Some studies suggest that certain *ACE2* variants are associated with a better blood pressure response to ACEI therapy, although the results are not entirely consistent [14]. Furthermore, the relationship between *ACE2* genetic variants and circulating levels of ACE2 and its metabolites (Ang II, Ang-(1–7)) has been explored, with some variants showing significant associations [15]. This information could eventually be used to personalize RAAS-targeted therapies.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and identifiers for the *ACE2* gene and its protein product, which are essential for bioinformatic analyses.

| **Database** | **Identifier** | **Description** |
| :--- | :--- | :--- |
| **NCBI Gene** | 59272 | GeneID for *ACE2* |
| **Ensembl** | ENSG00000130234 | Ensembl Gene ID |
| **UniProtKB/Swiss-Prot** | Q9BYF1 | Primary protein sequence and annotation |
| **RCSB [Protein Data Bank](/knowledge/bioinformatics/protein-data-bank-formats-archival-validation) (PDB)** | 6M0J | Cryo-EM structure of full-length human ACE2 with SARS-CoV-2 RBD |
| **OMIM** | 300335 | Online Mendelian Inheritance in Man entry |
| **HGNC** | 13557 | HUGO Gene Nomenclature Committee symbol |
| **RefSeq (mRNA)** | NM_021804.3 | Canonical transcript sequence |
| **RefSeq (Protein)** | NP_068576.1 | Canonical protein sequence |
| **Gene Ontology (GO)** | GO:0004181 (metallocarboxypeptidase activity); GO:0006508 (proteolysis); GO:0016021 (integral component of membrane) | Molecular function, biological process, cellular component |
| **STRING** | 9606.ENSP00000252519 | Protein-protein interaction networks |
| **BioGRID** | 121905 | Protein interaction database |
| **ClinVar** | Variants in *ACE2* | Clinical significance of genetic variants |

---

## Related Clinical & Scientific Guides

* [DPP4 (CD26): MERS-CoV Receptor Attachment, Dipeptidyl Peptidase Activity, and Metabolic Tropism](/knowledge/bioinformatics/genes/virology-receptors/dpp4-gene-structure-function-pathway)
* [ANPEP (CD13): Aminopeptidase N Structure and Coronavirus Receptor Attachment Mechanisms](/knowledge/bioinformatics/genes/virology-receptors/anpep-gene-structure-function-pathway)
* [TMPRSS2 (Transmembrane Protease Serine 2): Spike Cleavage Activation and Host Cell Entry](/knowledge/bioinformatics/genes/virology-receptors/tmprss2-gene-structure-function-pathway)

## References

[1] Li, M., Li, L., Zhang, Y., & Wang, X. (2020). An Investigation of the Expression of 2019 Novel Coronavirus Cell Receptor Gene ACE2 in a Wide Variety of Human Tissues. *Scientific Publication*. https://www.semanticscholar.org/paper/f0a1cc3c0a2f4009abff5c83aa7afe3eb5afd467

[2] Culebras, E., & Hernández, F. (2020). ACE2 is on the X chromosome: could this explain COVID-19 gender differences? *European Heart Journal*. https://www.semanticscholar.org/paper/7c467a4b29098f579c0f5821eca797d3328a09ac

[3] Kimura, H., Conway, M., Francisco, D., & Kraft, M. (2021). Type 2 Inflammation Reduces ACE2 Protein in Bronchial and Nasal Epithelial Cells. *Scientific Publication*. https://www.semanticscholar.org/paper/84d6dbb17a28fba1ffae996c0446075e4399435b

[4] Maas, A. (2021). COVID-19, the wake-up call for implementing sex and gender in cardiovascular disease. *Cardiovascular Research*. https://www.semanticscholar.org/paper/628da83655d0ce5d7574446f97315bc7128f454f

[5] Kroumpouzos, G. (2020). Effects of 5‐alpha reductase inhibitors on lung function: A reason for discontinuation during COVID‐19 pandemic? *Dermatologic Therapy*. https://www.semanticscholar.org/paper/c7d3e4307cf6ab02e5a6b55be2ce18332c6e4f0c

[6] Al-Azzawi, M. A., & Sakr, M. A. (2020). Co-Evolution between New Coronavirus (SARS-CoV-2) and Genetic Diversity: Insights on Population Susceptibility and Potential Therapeutic Innovations. *Scientific Publication*. https://www.semanticscholar.org/paper/e588a3e7ecd9295a347cabdc5e93088e673360f5

[7] Corley, M., & Ndhlovu, L. (2020). DNA Methylation Analysis of the COVID-19 Host Cell Receptor, Angiotensin I Converting Enzyme 2 Gene (ACE2) in the Respiratory System Reveal Age and Gender Differences. *Scientific Publication*. https://www.semanticscholar.org/paper/e0ef3c869d13c8afffbbf0c28a560676e4b69751

[8] Lippi, G., Lavie, C., Henry, B., & Sanchis-Gomar, F. (2020). Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)? *Clinical Chemistry and Laboratory Medicine*. https://www.semanticscholar.org/paper/6ee37a0158dcbaac829905ad95a87d6b8767c619

[9] Li, M., Li, L., Zhang, Y., & Wang, X. (2020). Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. *Infectious Diseases of Poverty*. https://www.semanticscholar.org/paper/850af40c5b31c48e46731717f2b248c4c51c11ea

[10] Benjafield, A., Wang, W. Y. S., & Morris, B. (2004). No association of Angiotensin-Converting enzyme 2 gene (ACE2) polymorphisms with essential hypertension. *American Journal of Hypertension*. https://www.semanticscholar.org/paper/0cf8e4ec5161ccf665c07cd9dcb170970b8721f4

[11] Huang, W., Yang, W., Wang, Y., Zhao, Q., Gu, D., & Chen, R. (2006). Association study of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms and essential hypertension in northern Han Chinese. *Journal of Human Hypertension*. https://www.semanticscholar.org/paper/d329eeed05844a69998e017bda349fa43fe5317d

[12] Zhang, H., Penninger, J., Li, Y., Zhong, N., & Slutsky, A. S. (2020). Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Medicine*. https://www.semanticscholar.org/paper/344691fefbffe0d2b26a5e721f68e011121cd883

[13] Lieb, W., Graf, J., Götz, A., König, I., Mayer, B., Fischer, M., Stritzke, J., Hengstenberg, C., Holmer, S., Döring, A., Löwel, H., Schunkert, H., & Erdmann, J. (2005). Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. *Journal of Molecular Medicine*. https://www.semanticscholar.org/paper/ada188069ae5ef0f92443215a5400dcf077b5efc

[14] Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., Bao, L., Zhang, B., Liu, G., Wang, Z., Chappell, M., Liu, Y., Zheng, D., Leibbrandt, A., Wada, T., Slutsky, A. S., Liu, D., Qin, C., Jiang, C., & Penninger, J. (2005). A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. *Nature Medicine*. https://www.semanticscholar.org/paper/d99cfca5014e00d83bfe76ea156cc7af18d9da95

[15] Bunyavanich, S., Do, A. N., & Vicencio, A. (2020). Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults. *Journal of the American Medical Association (JAMA)*. https://www.semanticscholar.org/paper/ff19b70f9296f350dab87c5fc14c90cf884a7390

[16] Beyerstedt, S., Casaro, E. B., & Rangel, É. B. (2021). COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. *European Journal of Clinical Microbiology and